| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf6afdc16ee5518854b0e3299d734662
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b7e87f29e0db9416800cab4f60f6c468
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_397384a6d230e34cf9e18e9c7d9b0a03 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2013-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bfb71b41f75f0bbc9c7a05aaec758a88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_02005118981a69ab41b44b81fcaa618d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d979a1864b71a3971912c9d6b84d8fd3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dda608f957dcff83e5987ade37e92805
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1a2a6872b560954f5acfc420624570ed
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b852b4edba8d6303842789cdaa3c2aa9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_035ee57d24c479e59b6841c072a22aeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f218ca5a8550042ec9f3529d37fe44b0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49c1592e3fb7bf41fcc0186b95c1fd47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5bee3d2431a7575ab2b85098e0007ce |
| publicationDate |
2021-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3766903-A2 |
| titleOfInvention |
Bispecific anti claudin xcd3 antibodies for treatment of claudin expressing cancer diseases |
| abstract |
The present disclosure provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer. |
| priorityDate |
2012-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |